Previous 10 |
home / stock / rnugf / rnugf news
ReNeuron Group ([[RNUGF]]) announces that it has completed dosing of the first cohort of three subjects in the Phase 2a extension segment of the study testing its hRPC (human retinal progenitor cell) therapy in patients with inherited blindness-causing disorder retinitis pigmentosa ((RP)).Thi...
The following slide deck was published by ReNeuron Group plc in conjunction with their 2021 Q2 earnings call. For further details see: ReNeuron Group plc 2021 Q2 - Results - Earnings Call Presentation
ReNeuron Group plc (RNUGF) Q2 2020 Earnings Conference Call December 6, 2019 04:30 AM ET Company Participants Olav Hellebø - Chief Executive Officer Michael Hunt - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel, Nicolaus & Company, In...
Reneuron Group ( OTCPK:RNUGF ): 1H GAAP EPS of -12.3p. More news on: ReNeuron Group plc, Earnings news and commentary, Consumer stocks news, , Read more ...
The following slide deck was published by ReNeuron Group plc in conjunction with their 2020 Q2 earnings Read more ...
ReNeuron Group PLC (RNUGF) Q4 2019 Earnings Conference Call July 11, 2019, 05:00 ET Company Participants Olav Hellebø - CEO & Director Michael Hunt - CFO, Secretary & Executive Director Conference Call Participants Andy Smith - Edison Investment Research Christ...
The following slide deck was published by ReNeuron Group plc in conjunction with their 2019 Q4 earnings Read more ...
Reneuron Group ( OTCPK:RNUGF ): FY GAAP EPS of -$45.2p. More news on: ReNeuron Group plc, Earnings news and commentary, Consumer stocks news, , Read more ...
Deals and Financings Hansoh Pharma, an established drug company headquartered in Lianyungang, Jiangsu province, has once again filed for a Hong Kong IPO, which is rumored to seek between $500 million and $1 billion in new capital. In September 2018, Hansoh filed to raise between $1 billion...
News, Short Squeeze, Breakout and More Instantly...
ReNeuron Group Company Name:
RNUGF Stock Symbol:
OTCMKTS Market:
(NewsDirect) ReNeuron Group PLC executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors to pr...
LONDON, UK / ACCESSWIRE / October 10, 2022 / ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-...
LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. T...